Achieve Life Sciences (ACHV) Expected to Announce Quarterly Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) is projected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.06). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Trading Down 4.0 %

NASDAQ ACHV opened at $2.67 on Thursday. The business’s 50-day moving average price is $3.12 and its two-hundred day moving average price is $3.97. Achieve Life Sciences has a 12 month low of $2.51 and a 12 month high of $5.59. The firm has a market capitalization of $92.61 million, a PE ratio of -2.36 and a beta of 1.67. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31.

Insider Buying and Selling at Achieve Life Sciences

In other Achieve Life Sciences news, CFO Mark K. Oki acquired 10,000 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were bought at an average cost of $2.89 per share, with a total value of $28,900.00. Following the purchase, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at $28,900. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.00% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.